Decision Resources reports that Western Drug companies can expect modest increase in market share

The colorectal cancer drug market in China will be worth US$ 290 million in 2012 more than a two-fold increase from US$ 118 million in 2001 according to Decision Resources a leading research and advisory firm. A substantial increase in colorectal cancer incident cases, improvements in access to medical care and significant increase in targeted therapy prescriptions are expected to fuel the growth.
"The increased use of Merck KGaA's Erbitux and Jiangsu Simcere's Endostar and the launch of Roche's Avastin will be the strongest drivers of the Chinese colorectal drug market during the next five years," stated Jing Wu, M.S., MBA. "We also expect a high uptake of Roche's Xeloda -- an oral pro-drug of 5-fluorouracil (5-FU) -- due to its delivery advantage over intravenous 5-FU and its inclusion on the National Reimbursement Drug List."
The report also indicates that Western Drug companies can expect a modest increase in their market share largely due to the increased usage of Western-branded drugs, targeted agents and decreasing market share of conventional chemotherapy drugs.

Comments

Search RSS

All rights reserved."